News

A new study out of Guangzhou, China found that individuals younger than 18 years of age and experiencing high myopia are at a high risk of progressively worsening myopic maculopathy.

The agreement settles Zeiss’s lawsuit against Topcon’s U.S.-based subsidiaries that had been set to start this month in U.S. federal court for the Northern District of California.

In a news release, the FDA noted these are copycat eye drop products that consumers can easily mistake for Bausch + Lomb’s Lumify brand eye drops, an over-the-counter product approved for redness relief.

According to the company, the deals from two global Phase III RVO studies will be presented at Angiogenesis, Exudation, and Degeneration 2024.

This presentation will outline the safety and bioactivity of KSI-501ABC in patients with diabetic macular edema (DME).

A University of Houston professor found that the excitement over the results of LLR as a treatment option for patients with myopia may have come too soon, before its efficacy was confirmed. One company is taking exception with the study.

Many options with one single Nd:YAG laser

Wilmer's expansive focus and deep bench are advancing the understanding of artificial intelligence tools and potential ophthalmic applications.

Enhanced detection and diagnosis of common and severe diseases

The licensing deal includes upfront, development milestones, and sales royalties, with additional considerations throughout the term of the agreement.

An in-depth case study conversation

Sanders is affiliated with the Retina Group of Washington (RGW) and PRISM Vision Group. He is the first African American and the first PRISM-affiliated physician to serve as president of the ASRS.

The study also pointed out the insight into the genes and biologic pathways that determine retinal health, which could be leveraged to develop future therapies.

Researchers at Mass Eye and Ear have demonstrated that retinal imaging can help predict a person’s risk of developing ocular, neuropsychiatric, cardiac, metabolic, and pulmonary diseases.

Joshua Mali, MD, offers up his predictions for ophthalmology in 2024.

Standalone, minimally-invasive glaucoma treatments

LambdaVision is leveraging the microgravity environment of the space station to develop higher-quality implants than is currently possible on Earth.

LambdaVision is leveraging the microgravity environment of the space station to develop higher-quality implants than is currently possible on Earth.

According to the company, ACDN-01 is the first-ever RNA exon editor to enter clinical development and the only clinical-stage therapeutic targeting the genetic cause of Stargardt disease. Ascidian expects to initiate enrollment in Phase 1/2 STELLAR study in the first half of 2024.

ACDN-01 is the first-ever RNA exon editor to enter clinical development and the only clinical-stage therapeutic targeting the genetic cause of Stargardt disease. Ascidian expects to initiate enrollment in Phase 1/2 STELLAR study in the first half of 2024.

Ophthalmologist shares pearls from recent roundtable discussion on topic.

The afternoon sessions begin after lunch and continue well into the evening at the Angiogenesis, Exudation, and Degeneration 2024 meeting

The one-day event will be held online Saturday, February 3, 2024, and is sponsored by the Bascom Palmer Eye Institute, University of Miami Health System

David Hutton of Ophthalmology Times talks with Jeffrey Cleland, PhD, President and CEO of Ashvattha Therapeutics, about the company's D-4517.2, a unique nanomedicine technology for the treatment of wet AMD and DME.

The afternoon sessions promise to be engaging and informative in this virtual conference.

While the potential for fundus images is recognized, the methodology and clinical application must be improved.

John T. Thompson, MD, FASRS, shares pearls for navigating the diverse landscape of career paths in ophthalmology as the Distinguished Guest Speaker at the 24th Annual Retina Fellows Forum.